Blockade of CTLA-4 increases anti-tumor response inducing potential of dendritic cell vaccine
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2020-06-21 / J Control Release 2020 Jun;326:63-74Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy
/in Dendritic Cells, International Publications /von 2020-06-15 / Nanomedicine 2020 Jun;29:102240Dendritic cell vaccine as an alternative to opioid analgesia in patients with advanced cervical cancer.
/in Cervical Cancer, Dendritic Cells, International Publications /von 2020-05-29 / J Clin Oncol 38: 2020 (suppl; abstr e18022)Dendritic Cell-Based Therapy Using LY6E Peptide with a Putative Role Against Colorectal Cancer
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2020-05-22 / Immunotargets Ther 2020;9:95-104Dendritic Cells and Their Role in Immunotherapy
/in Dendritic Cells, International Publications /von 2020-05-21 / Front Immunol 2020;11:924Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience
/in Brain Tumors in Children, Dendritic Cells, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2020-05-19 / Medicines (Basel) 2020 May;7(5)Feasibility of dendritic cell-based vaccine against glioblastoma by using cytoplasmic transduction peptide (CTP)-fused protein antigens combined with anti-PD1
/in Dendritic Cells, Glioblastoma, International Publications /von 2020-05-13 / Hum Vaccin Immunother 2020 May;:1-9Ex vivo pulsed dendritic cell vaccination against cancer
/in Dendritic Cells, International Publications /von 2020-05-04 / Acta Pharmacol Sin 2020 Jul;41(7):959-969Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2020-04-22 / Curr. Opin. Biotechnol. 2020 Apr;65:190-196
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de